Research & Publications

Translational research has always been the linchpin of Lifedoc’s clinical framework, further enabling us to provide healthcare that is quality-oriented and data-driven. Over the last 15 years, research has remained an integral part of our efforts to maximize the applicability of health data. With active participation in industry-sponsored and investigator-initiated research, we aim to to inform emerging treatments and continually refine our clinical model for the ultimate benefit of the patient. This focus allows us to continually develop data to support our evidence-based approach, ensuring that our patients receive the most effective healthcare and clinical interventions. Ultimately, this allows us to fulfill our mission of establishing Lifedoc as a reference model for researchers and practitioners studying the development and prevention of cardiometabolic conditions.

Take a look at our past and ongoing trials, research partnerships as well as some of our published/presented studies below.

Interested in working with our research site? Contact us.

Quality care for all. A kid playing doctor.

Research Partnerships

Novo Nordisk

Industry-sponsored Clinical Trials

Ongoing Trials

– Boehringer-Ingleheim – Safety and Efficacy of SGLT-2 and DPP-4 in Type 2 Diabetes, Children 10 – 17 years of age.

Past Trials

– Janssen – Safety and Efficacy of SGLT-2  in Type 2 Diabetes, Adults – Recognized as Highest Recruiting/Retaining Site in the US

– Novo Nordisk – Safety and Efficacy of Liraglutide in Overweight and Obesity, Children and Adolescents 10-17 years of age – Recruited First and Second Patient Globally

–  Novo Nordisk – Safety and Efficacy of Liraglutide and Metformin in Type 2 Diabetes, Children and Adolescents 10-17 years of age – Recognized as Highest Recruiting Site in the US

Notable Publications

Cardiometabolic risk factors in Venezuela. The EVESCAM study: a national cross-sectional survey in adults

Published: Primary Care Diabetes
Date:
Authors: Ramfis Nieto-Martínez, Juan P González-Rivas, Eunice Ugel, Maritza Duran, Eric Dávila, Ramez Constantino, Alberto García, Jeffrey I Mechanick, María Inés Marulanda
Abstract:
No previous study in Venezuela and few in the Region of the Americas have reported national cardiometabolic health data. Objectives: To determine the prevalence and distribution of cardiometabolic risk factors (CMRF) in adults of Venezuela.

Repositioning of the global epicentre of non-optimal cholesterol

Published: Nature
Date:
Authors: NCD Risk Factor Collaboration (NCD-RisC)
Abstract:
High blood cholesterol is typically considered a feature of wealthy western countries1,2. However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world3 and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health

A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity

Published: The New England Journal of Medicine
Date:
Authors: Aaron S Kelly 1 , Pernille Auerbach 1 , Margarita Barrientos-Perez 1 , Inge Gies 1 , Paula M Hale 1 , Claude Marcus 1 , Lucy D Mastrandrea 1 , Nandana Prabhu 1 , Silva Arslanian 1 , NN8022-4180 Trial Investigators
Abstract:
Background: Obesity is a chronic disease with limited treatment options in pediatric patients. Liraglutide may be useful for weight management in adolescents with obesity.

Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight

Published: Diabetes Care
Date:
Authors: William I Sivitz 1 , Lawrence S Phillips 2 3 , Deborah J Wexler 4 , Stephen P Fortmann 5 , Anne W Camp 6 , Margaret Tiktin 7 , Magalys Perez 6 , Jacqueline Craig 8 , Priscilla A Hollander 9 , Andrea Cherrington 10 , Vanita R Aroda 11 , Meng Hee Tan 12 , Jonathan Krakoff 13 , Neda Rasouli 14 , Nicole M Butera 15 , Naji Younes 15 , GRADE Research Group
Abstract:
We evaluated the effect of optimizing metformin dosing on glycemia and body weight in type 2 diabetes.

Trends in cardiometabolic risk factors in the Americas between 1980 and 2014: a pooled analysis of population-based surveys

Published: The Lancet Global Health
Date:
Authors: NCD Risk Factor Collaboration (NCD-RisC)—Americas Working Group
Abstract:
Describing the prevalence and trends of cardiometabolic risk factors that are associated with non-communicable diseases (NCDs) is crucial for monitoring progress, planning prevention, and providing evidence to support policy efforts. We aimed to analyze the transition in body-mass index (BMI), obesity, blood pressure, raised blood pressure, and diabetes in the Americas, between 1980 and 2014.
1 2 3 … 12

Contact Us